Clark Capital Management Group Invests $7.56M in Amphastar Pharmaceuticals

Firm purchases 283,674 shares of the drug company's stock

Mar. 16, 2026 at 9:09am

Got story updates? Submit your updates here. ›

Clark Capital Management Group Inc. purchased a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the third quarter, according to a recent SEC filing. The firm bought 283,674 shares of the company's stock, valued at approximately $7,560,000, making it a 0.62% owner of Amphastar Pharmaceuticals.

Why it matters

This investment by Clark Capital Management Group highlights institutional interest in Amphastar Pharmaceuticals, a specialty pharmaceutical company focused on injectable and inhalation products. As Amphastar continues to develop its portfolio of generic and proprietary drugs, the company's stock has drawn the attention of major investment firms.

The details

According to the SEC filing, Clark Capital Management Group purchased the 283,674 shares of Amphastar Pharmaceuticals in the third quarter. This stake represents approximately 0.62% ownership of the company. Several other hedge funds and institutional investors have also recently made changes to their positions in Amphastar, with some increasing their holdings significantly in the last quarter.

  • Clark Capital Management Group purchased the Amphastar shares in the third quarter.

The players

Clark Capital Management Group Inc.

An investment management firm that purchased a new stake in Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc.

A specialty pharmaceutical company headquartered in Rancho Cucamonga, California that focuses on the development, manufacturing and commercialization of injectable and inhalation products.

Got photos? Submit your photos here. ›

The takeaway

This investment by a major institutional investor like Clark Capital Management Group suggests growing confidence in Amphastar Pharmaceuticals' ability to continue developing its portfolio of generic and proprietary drug products. As the company navigates the pharmaceutical industry, this influx of capital could help support its ongoing research and development efforts.